PURPOSE: A pretherapy 124I-metaiodobenzylguanidine (MIBG) positron emission tomography (PET)/computed tomography (CT) provides a potential method to estimate radiation dose to normal organs, as well as tumors prior to 131I-MIBG treatment of neuroblastoma or pheochromocytoma. The aim of this work was to estimate human-equivalent internal radiation dose of 124I-MIBG using PET/CT data in a murine xenograft model. METHODS: Athymic mice subcutaneously implanted with NB1691 cells that express high levels of human norepinephrine transporter (n = 4) were imaged using small animal microPET/CT over 96 h (approximate imaging time points: 0.5, 2, 24, 52, and 96 h) after intravenous administration of 3.07-4.84 MBq of 124I-MIBG via tail vein. The tumors did not accumulate 124I-MIBG to a detectable level. All four animals were considered as control and organ radiation dosimetry was performed. Volumes of interest were drawn on the coregistered CT images for thyroid, heart, lung, liver, kidney, and bladder, and transferred to PET images to obtain pharmacokinetic data. Based on tabulated organ mass distributions for both mice and adult male human, preclinical pharmacokinetic data were extrapolated to their human-equivalent values. Radiation dose estimations for different age groups were performed using the OLINDA/EXM software with modified tissue weighting factors in the recent International Commission on Radiological Protection (ICRP) Publication 103. RESULTS: The mean effective dose from 124I-MIBG using weighting factors from ICRP 103 to the adult male was estimated at 0.25 mSv/MBq. In different age groups, effective doses using values from ICRP 103 were estimated as follows: Adult female: 0.34, 15-yr-old: 0.39 mSv/MBq, 10-yr-old: 0.58 mSv/MBq, 5-yr-old: 1.03 mSv/MBq, 1-yr-old: 1.92 mSv/MBq, and newborn: 3.75 mSv/ MBq. For comparison, the reported effective dose equivalent of 124I-NaI for adult male (25% thyroid uptake, MIRD Dose Estimate Report No. 5) was 6.5 mSv/MBq. CONCLUSIONS: The authors estimated human-equivalent internal radiation dose of 124I-MIBG using preclinical imaging data. As a reference, the effective dose estimation showed that 124I-MIBG would deliver less radiation dose than 124I-NaI, a radiotracer already being used in patients with thyroid cancer.
PURPOSE: A pretherapy 124I-metaiodobenzylguanidine (MIBG) positron emission tomography (PET)/computed tomography (CT) provides a potential method to estimate radiation dose to normal organs, as well as tumors prior to 131I-MIBG treatment of neuroblastoma or pheochromocytoma. The aim of this work was to estimate human-equivalent internal radiation dose of 124I-MIBG using PET/CT data in a murine xenograft model. METHODS: Athymic mice subcutaneously implanted with NB1691 cells that express high levels of human norepinephrine transporter (n = 4) were imaged using small animal microPET/CT over 96 h (approximate imaging time points: 0.5, 2, 24, 52, and 96 h) after intravenous administration of 3.07-4.84 MBq of 124I-MIBG via tail vein. The tumors did not accumulate 124I-MIBG to a detectable level. All four animals were considered as control and organ radiation dosimetry was performed. Volumes of interest were drawn on the coregistered CT images for thyroid, heart, lung, liver, kidney, and bladder, and transferred to PET images to obtain pharmacokinetic data. Based on tabulated organ mass distributions for both mice and adult male human, preclinical pharmacokinetic data were extrapolated to their human-equivalent values. Radiation dose estimations for different age groups were performed using the OLINDA/EXM software with modified tissue weighting factors in the recent International Commission on Radiological Protection (ICRP) Publication 103. RESULTS: The mean effective dose from 124I-MIBG using weighting factors from ICRP 103 to the adult male was estimated at 0.25 mSv/MBq. In different age groups, effective doses using values from ICRP 103 were estimated as follows: Adult female: 0.34, 15-yr-old: 0.39 mSv/MBq, 10-yr-old: 0.58 mSv/MBq, 5-yr-old: 1.03 mSv/MBq, 1-yr-old: 1.92 mSv/MBq, and newborn: 3.75 mSv/ MBq. For comparison, the reported effective dose equivalent of 124I-NaI for adult male (25% thyroid uptake, MIRD Dose Estimate Report No. 5) was 6.5 mSv/MBq. CONCLUSIONS: The authors estimated human-equivalent internal radiation dose of 124I-MIBG using preclinical imaging data. As a reference, the effective dose estimation showed that 124I-MIBG would deliver less radiation dose than 124I-NaI, a radiotracer already being used in patients with thyroid cancer.
Authors: Veerle Kersemans; Bart Cornelissen; Klaus Bacher; Ken Kersemans; Hubert Thierens; Rudi A Dierckx; Bart De Spiegeleer; Guido Slegers; John Mertens Journal: J Nucl Med Date: 2005-12 Impact factor: 10.057
Authors: L S Freudenberg; G Antoch; R Görges; J Knust; R Pink; W Jentzen; J F Debatin; W Brandau; A Bockisch; J Stattaus Journal: Eur Radiol Date: 2003-12 Impact factor: 5.315
Authors: Katherine K Matthay; Gregory Yanik; Julia Messina; Alekist Quach; John Huberty; Su-Chun Cheng; Janet Veatch; Robert Goldsby; Patricia Brophy; Leslie S Kersun; Randall A Hawkins; John M Maris Journal: J Clin Oncol Date: 2007-03-20 Impact factor: 44.544
Authors: Hanwen Zhang; Ruimin Huang; NagaVaraKishore Pillarsetty; Daniel L J Thorek; Ganesan Vaidyanathan; Inna Serganova; Ronald G Blasberg; Jason S Lewis Journal: Eur J Nucl Med Mol Imaging Date: 2013-10-31 Impact factor: 9.236
Authors: Zvi Bar-Sever; Lorenzo Biassoni; Barry Shulkin; Grace Kong; Michael S Hofman; Egesta Lopci; Irina Manea; Jacek Koziorowski; Rita Castellani; Ariane Boubaker; Bieke Lambert; Thomas Pfluger; Helen Nadel; Susan Sharp; Francesco Giammarile Journal: Eur J Nucl Med Mol Imaging Date: 2018-10 Impact factor: 9.236
Authors: Ian R Marsh; Joseph Grudzinski; Dana C Baiu; Abigail Besemer; Reinier Hernandez; Justin J Jeffery; Jamey P Weichert; Mario Otto; Bryan P Bednarz Journal: J Nucl Med Date: 2019-03-29 Impact factor: 10.057
Authors: Youngho Seo; W Clay Gustafson; Shorouk F Dannoon; Erin A Nekritz; Chang-Lae Lee; Stephanie T Murphy; Henry F VanBrocklin; Miguel Hernandez-Pampaloni; Daphne A Haas-Kogan; William A Weiss; Katherine K Matthay Journal: Mol Imaging Biol Date: 2012-12 Impact factor: 3.488
Authors: Shih-ying Huang; Wesley E Bolch; Choonsik Lee; Henry F Van Brocklin; Miguel H Pampaloni; Randall A Hawkins; Aimee Sznewajs; Steven G DuBois; Katherine K Matthay; Youngho Seo Journal: Mol Imaging Biol Date: 2015-04 Impact factor: 3.488
Authors: Hanwen Zhang; Ruimin Huang; Nai-Kong V Cheung; Hongfen Guo; Pat B Zanzonico; Howard T Thaler; Jason S Lewis; Ronald G Blasberg Journal: Clin Cancer Res Date: 2014-02-26 Impact factor: 12.531